Inspire Medical Systems, Inc. INSP
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 10, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
29 paragraphs in Risk Factors of the 10-K filed Feb 13, 2026 with nothing like them in the 10-K filed Feb 10, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
•lack of availability of adequate or clear third-party payor coverage or reimbursement;
reducing the BMI of our prospective patients and increasing the number of eligible patients for our Inspire therapy, there can be no assurance of such benefit.
Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6, 2025, the City of Pontiac Reestablished General Employees’ Retirement System, on behalf of itself and other similarly situated investors, filed a putative securities class action in the United States District Court for the District of Minnesota against the Company and certain of its executive officers, captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., Case No. 0:25‑cv‑04247‑PJS‑ECW (D. Minn.) (the “City of Pontiac Lawsuit”). The complaint alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b‑5 promulgated thereunder, based on purportedly materially false and misleading statements made between August 6, 2024, and August 4, 2025, regarding the launch of the Company’s Inspire V neurostimulator. The complaint further alleged that when subsequent disclosures were made concerning issues with the Inspire V launch and the Company announced its third‑quarter fiscal 2025 results, the Company’s stock price declined, purportedly causing investor losses. On December 23, 2025, the plaintiff filed a Notice of Voluntary Dismissal. On December 29, 2025, the case was administratively closed without prejudice.
On December 22, 2025, the Indiana Public Retirement System, on behalf of itself and other similarly situated investors, filed a putative securities class action in the United States District Court for the Southern District of New York against the Company and certain of its executive officers, captioned Indiana Public Retirement System v. Inspire Medical Systems, Inc., et al., Case No. 1:25‑cv‑10620 (S.D.N.Y.) (the “Indiana PRS Lawsuit”). The Indiana PRS Lawsuit arises from the same underlying subject matter as the City of Pontiac Lawsuit. It alleges the same violations of law and is based on the same or similar purportedly materially false and misleading statements made during the same class period, all of which relate to the launch of the Company’s Inspire V neurostimulator. The plaintiffs seek, among other relief, unquantified compensatory damages, together with attorneys’ fees and costs. On January 22, 2026, the Company and the individual defendants moved to transfer the case to the United States District Court for the District of Minnesota. That motion remains pending. The Company and the individual defendants intend to vigorously defend against the action. No accrual for loss has been accrued or recorded in the Company’s financial statements as of, or for the period ended, December 31, 2025 since the Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss.
In addition, we are currently a party to multiple adversarial proceedings with Nyxoah regarding our patent portfolio and the patents of third parties. For additional information, see Note 11, Commitments and Contingencies to the
to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for our Inspire system and our results of operations.
Show the other 15
•unforeseen cultural attitudes that result in fewer potential patients having interest in surgery or a medical device such as our Inspire therapy; and
In the course of conducting our business, we must adequately address quality issues that may arise with our Inspire system, including defects in third-party components included in our Inspire system. There can be no
We rely extensively on information technology systems to conduct our business and collect, store, process and transmit confidential and sensitive information, including personal information of (or relating to) customers, patients and our employees and contractors. These systems support, among other things, manufacturing and distribution, supply chain management, order processing, financial reporting, patients, regulatory and legal compliance and other critical business functions. Our information technology systems, operational technology environments, and those of our third-party service providers, vendors, contract manufacturers, strategic partners and other contractors or consultants are vulnerable to evolving cybersecurity threats. These threats include, but
are not limited to, damage or interruption from computer viruses and malware (e.g. ransomware), misconfigurations, “bugs” or other vulnerabilities, malicious code, terrorism, telecommunication and electrical failures, hacking, cyberattacks, phishing and other social engineering attacks, denial of service attacks, insider threats, human error, fraud, unauthorized access, and attacks by sophisticated nation-state and nation-state-supported actors. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information.
utilized and our federal R&D credit carryover was $10.1 million. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a change of ownership within the definition of Section 382 of the Code, we may not be able to utilize a material portion of the remaining R&D credit carryforwards, even if we sustain profitability.
Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.
We are subject to taxes by the U.S. federal, state, and local tax authorities. We record income tax expense based on our estimates of future payments, which may include the recording of, or adjustments to, liabilities for uncertain tax positions, and changes in the valuation allowance related to our net deferred tax assets. In addition, at any one time multiple tax years may be subject to audit by various tax authorities. The results of these audits and negotiations with taxing authorities may affect the ultimate settlement of these issues and impact our results of operations. We expect that during fiscal year 2026 and beyond there could be ongoing variability in our effective tax rate as events occur and exposures are evaluated. The volatility of our future effective tax rate could be materially impacted by a number of factors, including:
•expected timing and amount of the release of any valuation allowance on our deferred tax assets; or
•changes in U.S. federal, state and local tax rates, tax laws, regulations, or interpretations thereof.
In addition, our effective tax rate in a given financial statement period may be materially impacted by a variety of factors including, but not limited to, changes in the mix and level of earnings, deductible expenses and availability of NOLs in the different states in which we operate, fluctuations in the valuation allowance on our deferred tax assets, or by changes to existing accounting rules or regulations. Further, tax legislation may be enacted or amended, as applicable, in the future which could materially impact our current or future tax structure and effective tax rates. We may be subject to audits of our income, sales, and other transaction taxes by U.S. federal, state, and local taxing authorities. Outcomes from these audits could have a material effect on our financial condition or financial results.
Climate-related events, geopolitical and global events, and other events could harm our business.
subcontractors. Our products are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing.
any case, would entail significant cost and could harm our reputation, business, financial condition, and results of operations.
have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.
Our business may be affected by the evolving regulatory framework for AI Technologies.
The regulatory framework for artificial intelligence (“AI”), machine learning, and automated decision-making technologies (collectively, “AI Technologies”) is rapidly evolving as many federal, state, and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. Additionally, existing laws and regulations may be interpreted in ways that would affect the operation of our AI Technologies.
It is possible that new laws and regulations will be adopted in the United States and in other non-U.S. jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be interpreted in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that negatively affects the performance of our products, services, and business and the way in which we use AI Technologies. We may need to expend resources to adjust our products or services in certain jurisdictions if the laws, regulations, or decisions are not consistent across jurisdictions. Further, the cost to comply with such laws, regulations, or decisions and/or guidance interpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in operating expenses, as well as any actual or perceived failure to comply with such laws and regulations, could adversely affect our business, financial condition and results of operations.
In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs, and there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for our product. New and changing laws and regulations may also create uncertainty about how such laws and regulations will be interpreted and applied. If we are found to have violated laws and regulations, it could materially adversely affect our business, results of operations and financial condition.
The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect sales of our Inspire system.
•patients may be harmed in the course of the clinical study negatively impacting Inspire’s brand, reputation, and business;
employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect such agencies’ ability to conduct routine activities.
Our commercial success may depend in part on allegations from third parties alleging that we are infringing their patents or violating their other proprietary rights. Significant litigation regarding patent rights occurs in our industry. Our competitors in both the U.S. and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may
tribunal for challenging patents could increase the likelihood that our own patents will be challenged, thereby increasing the uncertainties and costs of maintaining and enforcing them.
Paragraphs in the 10-Q filed Nov 2, 2026 that were not in the one before
New in the latest 10-Q
8 paragraphs in the 10-Q filed Nov 2, 2026 with nothing like them in the 10-Q filed Aug 3, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in select countries in Europe and the Asia Pacific region. We do not have any intra-entity sales or transfers.
Read in the 10-Q
On January 30, 2026, a putative class action captioned Zeller v. Inspire Medical Systems, Inc. was filed against the Company in the U.S. District Court for the District of Minnesota. The complaint alleged that third-party tracking technologies on our website captured and transmitted users' information to third parties without their knowledge or consent. It asserted claims under the Electronic Communications Privacy Act and the Minnesota wiretap statute, as well as common law claims. On July 28, 2026, a putative class action making similar allegations on behalf of California residents, captioned Brookshier et al. v. Inspire Medical Systems, Inc., was filed against us in the Superior Court of California, County of San Mateo. That complaint asserted claims under the California Invasion of Privacy Act, for breach of contract, and under California's Unfair Competition Law. In September 2026, both actions were voluntarily dismissed without prejudice to facilitate the parties’ participation in mediation. On October 5, 2026, following mediation, we entered into a binding term sheet with the named plaintiffs in both actions. The term sheet contemplates filing a new putative class action asserting the same or similar claims, which would be settled on behalf of a nationwide settlement class. Under the term sheet, we will pay $ 7.0 million into a settlement fund, which
Read in the 10-Q
will also cover notice and administration costs and any court-approved attorneys' fees, costs and service awards. The settlement is subject to execution of a definitive settlement agreement and approval by the court in the new action. We deny the allegations and any liability, and we agreed to the proposed settlement solely to avoid the expense, burden and uncertainty of further litigation. We incurred $ 7.0 million of legal settlement expense in the third quarter of 2026 related to this matter.
Read in the 10-Q
In the third quarter of 2026, we incurred $ 24.1 million of pre-tax restructuring charges, of which $ 1.3 million was included within R&D expense and $ 22.8 million was included within SG&A expense:
Read in the 10-Q
As a result of the decision to cease certain manufacturing activities, we determined that the carrying amounts of certain production equipment were no longer recoverable and therefore reduced the carrying amounts of the assets to their estimated fair value, resulting in non-cash asset impairment charges of $ 21.1 million, which were recognized within SG&A expense. The estimated fair value of certain production equipment that we do not expect to utilize or sell was estimated to be zero because the equipment had no alternative use or expected disposal proceeds.
Read in the 10-Q
Show the other 3
The restructuring accrual balance included in accrued expenses on the consolidated balance sheets was $ 1.5 million at September 30, 2026 and relates to employee severance and termination benefits. The majority of the accrued balance is expected to be paid during the fourth quarter of 2026 and early 2027. The restructuring accrual excludes non-cash charges and other costs that were recognized directly in earnings as incurred.
Read in the 10-Q
On October 5, 2026, we entered into a binding term sheet to settle a class action related to allegations concerning our use of pixel-tracking technology on our website and the disclosure of certain information to third parties (Zeller v. Inspire Medical Systems, Inc.). See Note 9, “Commitments and Contingencies,” for additional information.
Read in the 10-Q
In September 2026, the AMA approved the establishment of a new set of Category I CPT codes which are scheduled to take effect on January 1, 2028. With the new codes created, the CMS will conduct its standard process to determine the value for each new CPT code, which determines the payments for that service under Medicare. We expect that CMS will issue their proposed valuation in July 2027 with final valuations issued in November 2027 and effective January 1, 2028. The use of any -52 modifier for professional billing will no longer be needed at this time due to the new code.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 2, 2026 against Item 1A of the 10-K filed Feb 13, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 13, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 10, 2025
Where each one is used
- current presidential: •changing tariffs and trade barriers, including recent and proposed changes in tariffs imposed by the current U.S. presidential administration and any retaliatory tariffs by other countries;
- presidential administration: •changing tariffs and trade barriers, including recent and proposed changes in tariffs imposed by the current U.S. presidential administration and any retaliatory tariffs by other countries;
- retirement system: Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6,...
- tax rate: Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.
- deferred tax: Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.
- tax assets: Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.
- inspire medical: Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6,...
- medical systems: Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6,...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
17 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.